Microbiome alterations in mismatch-repair deficient metastatic colorectal cancer patients
The microbiome links with other tumor characteristics remain underinvestigated, including those related to microsatellite instability, that have so far been assessed only with respect to intratumoral bacterial presence and not to the whole gut or oral microbiome.
Colorectal cancer (CRC) is the second leading cause of cancer‑related death worldwide. Many efforts have been made to stratify CRC cases, from investigating the genomic characteristics of the tumor to – more recently – considering the gut microbiome. Differences in the composition of the gut microbiome occur along CRC stages and according to primary tumor location. The microbiome links with other tumor characteristics remain underinvestigated, including those related to microsatellite instability, that have so far been assessed only with respect to intratumoral bacterial presence and not to the whole gut or oral microbiome. Here we study associations between tumor microsatellite instability and the microbiome by collecting oral and gut microbiome samples from two clinical trials, ARETHUSA and AtezoTRIBE, enrolling metastatic CRC (mCRC) patients with microsatellite stable (MSS) tumors and with high microsatellite instability (MSI‑H) tumors. We identified a significant reduction in microbial diversity in oral and gut microbiomes of CRC patients with MSI‑H compared to patients with MSS (Wilcoxon rank‑sum test P = 0.001 and 0.005, respectively). In addition, the MSI‑H condition could be predicted by machine learning algorithms (AUC of 0.7 for both stool and oral microbiome) and the microbial signature for this condition comprises fewer microbial species compared to MSS with Ligilactobacillus salivarius and Rothia mucilaginosa detected as the strongest MSI‑H associated intestinal and oral species, respectively. Our work provides evidence of human microbiome connections with tumor genetic stability, and poses the basis for larger validating investigations and mechanistic studies.
The study demonstrates a significant reduction in microbial diversity in the gut and oral microbiomes of metastatic colorectal cancer patients with high microsatellite instability (MSI‑H) compared to microsatellite stable (MSS) patients and shows that MSI‑H status can be predicted by machine learning with an area‑under‑the‑curve of 0.7 from stool and oral microbiome data. This highlights the potential of the microbiome as a non‑invasive biomarker for tumor genetic stability and may inform future therapeutic strategies targeting the microbiome in MSI‑H colorectal cancer.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics